In This Article:
RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Enlivex is pioneering macrophage reprogramming immunotherapy with its Allocetra™ platform, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This innovative approach aims to address critical medical challenges, including life-threatening conditions such as sepsis and debilitating diseases like osteoarthritis. With promising Phase I/II clinical trial results in multiple indications, including knee osteoarthritis and psoriatic arthritis, Enlivex is advancing Allocetra™ as a potential game-changer for millions of patients globally. In 2024, the company achieved a significant milestone with the initiation of a multi-country, randomized trial evaluating Allocetra™ in up to 160 patients with moderate to severe knee osteoarthritis, which is expected to generate key data by Q3 2025, paving the way for future therapeutic breakthroughs.
Maria Zannes, President and CEO of bioAffinity, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath® Lung. CyPath® Lung improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath® Lung, making the test available to U.S. veterans and federal health service patients, which is expected to accelerate sales growth in the quarters ahead.
Enlivex and bioAffinity are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Enlivex
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.